UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
 
Date of Report (Date of earliest event reported)   March 2, 2006
 
Interpharm Holdings, Inc.
(Exact name of Registrant as specified in charter)

Delaware
0-22710
13-3673965
(State or other
jurisdiction of incorporation)
(Commission
File Number) 
(IRS Employer
Identification No.) 
     
75 Adams Avenue, Hauppauge, New York
11725
(Address of principal executive offices)
 (Zip Code)

Registrant's telephone number, including area code:   (631) 952-0214

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
Item 5.02 
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

It is with great regret that we disclose that on March 2, 2006, Munish Rametra, Interpharm Holdings, Inc.’s Executive Vice President and General Counsel passed away.


Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
     
  INTERPHARM HOLDINGS, INC.
 
 		  
 		  
 
March 7, 2006 By:   /s/ George Aronson
 
George Aronson
  Chief Financial Officer